National Screening Institute
More and more data on the benefits of low oxLDL is appearing in the literature. The results of 100s of studies clearly show that low oxidized LDL correlates with a lower probability of a variety of disease states, most caused by atherosclerosis.
National Screening Institute (NSI) has the exclusive worldwide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium. Testing kits (MTP format) are manufactured under license by Mercodia (Uppsala, Sweden). The test is made available to the public in the USA by Quest Diagnostics.